Literature DB >> 24297629

Oil Red O-assessed macrosteatosis in liver transplant donor biopsies predicts ischemia-reperfusion injury and clinical outcome.

Henning Reis1, Patricia T Peterek, Jeremias Wohlschlaeger, Gernot M Kaiser, Zoltan Mathe, Benjamin Juntermanns, Georgios C Sotiropoulos, Ulrich Beckhove, Ali Canbay, Ulrike Wirges, Andre Scherag, Juergen-Walter Treckmann, Andreas Paul, Hideo Andreas Baba.   

Abstract

Steatosis in donor livers is an accepted adverse prognostic factor after liver transplantation. While its semiquantitative assessment shows varying reproducibility, it is questioned as a standard method. Additionally, the influence of hepatic steatosis on ischemia/reperfusion injury (I/R injury) has not been evaluated in biopsies after reperfusion. We compared different staining and analyzing methods for the assessment of donor liver steatosis in order to predict I/R injury and clinical outcome after transplantation. To do this, 56 paired pre- and post-reperfusion liver biopsies were analyzed for macro- (MaS)/micro- (MiS) and total steatosis in cryo and permanent sections by special fat (Oil Red O or ORO) and standard stains. Computerized morphometrical analyses were compared to the semiquantitative assessment by a pathologist. I/R injury was determined histopathologically and by M30 immunohistochemistry. We found ORO to be more sensitive in detecting hepatic steatosis with higher reproducibility for MaS. Semiquantitative analyses were highly reproducible and not inferior to computerized morphometry. Categorized MaS as determined by ORO correlated with the extent of I/R injury, initial poor function, liver enzymes, and survival. Therefore fat stains like ORO are a reliable and easy method comprising significant advantages in the evaluation of hepatic steatosis and are thereby of prognostic value. Computerized analysis is a precise tool though not superior to semiquantitative analyses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297629     DOI: 10.1007/s00428-013-1512-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

Review 1.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

Review 2.  Steatosis as a risk factor in liver surgery.

Authors:  Reeta Veteläinen; Arlène van Vliet; Dirk J Gouma; Thomas M van Gulik
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants".

Authors:  Georgios C Sotiropoulos; Andreas Paul; Ernesto Molmenti; Hauke Lang; Andrea Frilling; Bogdan P Napieralski; Silvio Nadalin; Jürgen Treckmann; Eirini I Brokalaki; Till Gerling; Christoph E Broelsch; Massimo Malagó
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

4.  Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience.

Authors:  Matthias Heuer; Gernot M Kaiser; Alisan Kahraman; Mark Banysch; Fuat H Saner; Zoltan Mathé; Guido Gerken; Andreas Paul; Ali Canbay; Jürgen W Treckmann
Journal:  Digestion       Date:  2012-07-27       Impact factor: 3.216

5.  Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation.

Authors:  Beate Katharina Straub; Benedek Gyoengyoesi; Maria Koenig; Merita Hashani; Lena Maria Pawella; Esther Herpel; Wolf Mueller; Stephan Macher-Goeppinger; Hans Heid; Peter Schirmacher
Journal:  Histopathology       Date:  2013-01-24       Impact factor: 5.087

6.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

7.  Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters.

Authors:  B Cieślak; Z Lewandowski; M Urban; B Ziarkiewicz-Wróblewska; M Krawczyk
Journal:  Transplant Proc       Date:  2009-10       Impact factor: 1.066

8.  Correlation between selected prognostic factors and postoperative course in liver transplant recipients.

Authors:  W Patkowski; K Zieniewicz; M Skalski; M Krawczyk
Journal:  Transplant Proc       Date:  2009-10       Impact factor: 1.066

9.  Quantification of degree of steatosis in extended criteria donor grafts with standardized histologic techniques: implications for graft survival.

Authors:  F Frongillo; A W Avolio; E Nure; A Mulè; G Pepe; S C Magalini; S Agnes
Journal:  Transplant Proc       Date:  2009-05       Impact factor: 1.066

10.  Ischemia/Reperfusion injury in liver surgery and transplantation: pathophysiology.

Authors:  Kilian Weigand; Sylvia Brost; Niels Steinebrunner; Markus Büchler; Peter Schemmer; Martina Müller
Journal:  HPB Surg       Date:  2012-05-30
View more
  6 in total

Review 1.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

Review 2.  Donor liver histology--a valuable tool in graft selection.

Authors:  Christa Flechtenmacher; Peter Schirmacher; Peter Schemmer
Journal:  Langenbecks Arch Surg       Date:  2015-03-26       Impact factor: 3.445

Review 3.  [Donor liver histology : Joint recommendations of the DGP, DTG and DSO].

Authors:  C Schleicher; H-H Kreipe; P Schemmer; C P Strassburg; C-L Fischer-Fröhlich; A Rahmel; C Flechtenmacher
Journal:  Chirurg       Date:  2019-11       Impact factor: 0.955

4.  Liver steatosis in pre-transplant liver biopsies can be quantified rapidly and accurately by nuclear magnetic resonance analysis.

Authors:  Stefanie Bertram; Cathrin Myland; Sandra Swoboda; Anja Gallinat; Thomas Minor; Nils Lehmann; Michael Thie; Julia Kälsch; Leona Pott; Ali Canbay; Thomas Bajanowski; Henning Reis; Andreas Paul; Hideo A Baba
Journal:  Virchows Arch       Date:  2016-12-03       Impact factor: 4.064

5.  Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms.

Authors:  Yizhe Cui; Renxu Chang; Tao Zhang; Xiaocui Zhou; Qiuju Wang; Haiyun Gao; Lintong Hou; Juan J Loor; Chuang Xu
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

6.  Ex Vivo Fluorescence Confocal Microscopy in Specimens of the Liver: A Proof-of-Concept Study.

Authors:  Ulf Titze; Karl-Dietrich Sievert; Barbara Titze; Birte Schulz; Heiko Schlieker; Zsolt Madarasz; Christian Weise; Torsten Hansen
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.